US Antibody Engineering Xchange 2018
FULL AGENDA

ANTIBODY DISCOVERY Track

Time
Topic Title and Bullets
Facilitator

09:00-10:00

How to identify which is the best antibody platform to move forward with for lead identification?
• What should be the most important selection criteria?
• Deciding factors to weigh risk and value
• Technology evolution, why and how?
• What does the trajectory predict for the future?

Partha Chowdhury,
Senior Director &
Head, Antibody Discovery, Sanofi

10:30-11:30

Selection of antibodies specific for multi-pass membrane proteins using mammalian virus display
• What are the biggest challenges to overcome to enable selection of antibodies specific for multi-pass membrane proteins?
• What are the available technical solutions to these challenges?
• How can recombinant virus display and VLPs be used to overcome these challenges?

Ernest Smith,
Senior Vice President Research &
Chief Scientific Officer, Vaccinex

12:00-13:00

How to validate conformation-specific antigen targets?
• How do we know the selected antibodies bind a specific conformation such as a disease-specific form?
• How can we differentiate normal and disease-related forms?
• What methods can be used to validate protein conformations?

Michael Sierks,
Professor, Chemical Engineering,
Arizona State University

15:15-16:15

Applications of antibody decoding through protein sequencing
• Applications of protein sequencing- is DNA sequencing the only choice?
• Issues in antibody reproducibility and solutions. Is your mAb truly monoclonal?
• Advances in MS sequencing; does Ile/Leu differentiation matter?
• Future directions: MS sequencing in recombinant polyclonal antibodies

Anthony Stajduhar,
Manager, Sales & Business Development,
Rapid Novor

16:20-17:20

How to apply NGS technology to speedup Ab lead discovery and increase lead Ab sequence diversity
• Can NGS help your Ab discovery effort?
• NGS platform: MiSeq or HiSeq, which one is more suitable for Ab library sequencing?
• Sequencing Data analysis
• How to pick Ab hits from NGS sequencing results?

Zhinan Xia,
Senior Director, Henlix

ANTIBODY ENGINEERING Track

Time
Topic Title and Bullets
Facilitator

9:00-10:00

Antibody optimization strategies balancing antigen affinity, functional activity, and manufacturing developability
• Approaches to antigen affinity optimization – structure-based rational design vs high throughput screening vs phage display
• Optimization of effector function and multi-specificity subsequent or in parallel to affinity maturation
• When and how to assess developability potential of lead candidates

Clark Pan, Vice President,
Head of Discovery Therapeutics, Shire

10:30-11:30

A balanced approach to developability analysis throughout antibody discovery
• How early do we begin our developability assessments during the drug discovery process?
• How do we prioritise antibody attributes at each stage of the process?
• Which analytical approaches are most valuable in initial developability assessments?

Hugh Morgan,
Senior Scientist & Team Leader,
Antibody Purification and Analytics,
Fusion Antibodies

12:00-13:00

Antibody Fc engineering for PK and effector function modulation
• How low is low enough for antibody’s effector function when a silent Fc format is needed?
• What are the benefits of engineering for antibody that specifically binds to one type of FcγR?
• What other factors contribute to antibody PK beside FcRn binding?
• What are the major issues of the existing Fc formats?

Huawei Qiu,
Senior Director, Head of Protein Engineering,
Sanofi Genzymex

15:15-16:15

Overcoming design and evaluation challenges of next-generation cancer immunotherapies
• How to choose an appropriate antibody modality? Bispecific, ADC, CAR-T, fragment, monotherapy, combinations
• The relevance/translation of animal models, transgenics, surrogates
• How to choose and evaluate antibody subclass?

Yasmina Abdiche,
Chief Scientific Officer,
Carterra

16:20-17:20

New frontiers in precision medicine: Using patient’s own cells as an antibody production system for treatment of cancer
• Approaches to personalized antibody product
• Translating from animal models to practical impacts in patients
• Challenges of in-vivo antibodies half-life in different areas of the body, e.g., brain
• Overcoming anti-drug antibodies

Inbal Zafir-Lavie,
Senior Scientist, Translational Medicine,
Aevi Genomic Medicine

BISPECIFIC ANTIBODIES Track

Time
Topic Title and Bullets
Facilitator

9:00-10:00

Implementing strategies to enhance bispecific activity
• Current limitations of bispecifics for the treatment of solid tumor indications
a) On-target, off-tumor DLTs in the clinic
b) Lack of clean tumor targets for solid tumors
• Strategies to overcome current limitations of bispecifics for solid tumor targeting
a) Key differentiation between platforms
b) Technology and biology update

Hans-Peter Gerber,
President & Chief Scientific Officer,
Maverick Therapeutics

12:00-13:00

Bispecifics and CARs: Different challenges for anti-cancer vs. anti-HIV applications
• Duration of function
• Location, location, location
• Anti-drug antibodies

Edward Berger, Chief,
Molecular Structure Section, LVD, NIAID,
National Institutes of Health

16:20-17:20

Developing a plug-and-play platform approach for bispecific generation and development
• Optimal building blocks for bispecific engineering
• Impact of bispecific formats on pharmacological activities
• Impact of bispecific formats on developability

Chung-Ming Hsieh,
Executive Director, Biologics Discovery,
Merck

ANTIBODY DRUG CONJUGATES Track

Time
Topic Title and Bullets
Facilitator

09:00-10:00

Developing next-generation ADCs to improve therapeutic index
• Engineering homogeneous and stable ADCs – are we there yet to address the therapeutic Index of ADC?
• How to address the on-target toxicities associated with ADCs?
• How to address the off-target toxicities often observed in ADCs?
• How to optimize the linker and warhead for preferred killing of tumor cells?

Changshou Gao,
Senior Director & Fellow, R&D,
MedImmune

10:30-11:30

Linker-payload technologies: Where should the focus be to deliver improvements?
• Site specific conjugation chemistries?
• Payloads and attachment chemistry?
• Linkers?

Rory Curtis,
Vice President Discovery Biology & Pharmacology & Site Head,
AMRI

12:00-13:00

Translating ADCs from preclinical into clinical
• How can we use data from the clinical studies to improve the preclinical development of ADCs?
• How has ADC technology improved and what are the shortcomings?
• Will improvements in the preclinical development of ADCs improve the clinical success rates for ADCs?

Dowdy Jackson,
Director, Biological Sciences,
Ambrx

15:15-16:15

Antibody drug conjugates and mechanisms of resistance
• Does the unique structure and function of antibody-drug conjugates (ADCs) suggest specific mechanisms of primary resistance?
• How might some of the ADC components be modified to overcome these mechanisms of resistance?

James Huebner,
Principal, Pharminteg LLC

16:20-17:20

Hidden in plain sight: Secrets to building successful ADCs
• How do we design & interpret preclinical studies to be predictive of the clinic?
• How can we be more efficient: which assays matter, and which don’t?
• Which technologies are most promising for next-generation ADCs?
• Where is the greatest clinical opportunity for ADCs?

Marc Damelin,
Senior Director, Head of Biology,
Mersana Therapeutics

CANCER IMMUNOTHERAPIES Track

Time
Topic Title and Bullets
Facilitator

09:00-10:00

Designing multispecific antibody-based biotherapeutics for optimal anti-tumour responses
• What is needed to make informed choices about target selection?
• Platform modalities: does one size fit all?
• Limits of biology: biophysical properties of a drug vs target expression
• Is it all about T cells?

Theresa Goletz,
Global Head, NBE Drug Disposition,
EMD Serono

12:00-13:00

How to differentiate and stand out in a very competitive and crowded space
• How to overcome the limitations for the identification of novel targets
• Have the most relevant I/O targets already been exploited, which one will be the next frontier?
• Impact of Ab format on MOA and efficacy
• Will the future be dominated by single agents or combinations?

Horacio Nastri,
Senior Director, Antibody Biotherapeutics,
Incyte Corporation

15:15-16:15

ANTIBODY DISCOVERY TOPIC How to effectively use Rabbit monoclonal antibodies for therapeutic antibody discovery?
• Rabbit monoclonal antibodies as an antibody tool for therapeutic antibody discovery
• Which technique is better: B cell cloning or phage display?
• How to achieve high reproducibility of antibodies?

Li Hui,
Principal Scientist, Rabbit Monoclonal Antibody Discovery,
ABclonal

16:20-17:20

Developing bispecific antibodies for immuno-oncology
• Why a bispecific versus a combination of two antibodies?
• What valency of binding to each target is optimal for the desired mechanism of action?
• How do you select the optimal antibody specificities to function in context of a bispecific?

Paul Moore,
Vice President, Research,
MacroGenics